United Kingdom  

Oxycodone

Chemical compound

Oxycodone    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Oxycodone: Chemical compound
Oxycodone, sold under brand name OxyContin among others, is an opioid medication used for treatment of moderate to severe pain. It is usually taken by mouth, and is available in immediate-release and controlled-release formulations. Onset of pain relief typically begins within 15 minutes and lasts for up to six hours with the immediate-release formulation. In the United Kingdom, it is available by injection. Combination products are also available with paracetamol (acetaminophen) or aspirin.

0
shares
ShareTweetSavePostSend
 

You Might Like


Where the Purdue Pharma-Sackler legal saga stands

OxyContin maker Purdue Pharma LP and its controlling Sackler family have been negotiating with cities, counties and states on a proposed settlement worth an estimated $10 billion to resolve more than..
Reuters - Published

Exclusive: OxyContin maker Purdue is 'Pharma Co X' in U.S. opioid kickback probe - sources

OxyContin maker Purdue Pharma LP is the unnamed company that surfaced in criminal charging documents filed earlier this week in a probe of illegal kickbacks from drugmakers, according to people..
Reuters - Published

OxyContin maker Purdue Pharma to pay states' lawyers, urged to help victims

OxyContin maker Purdue Pharma LP got court approval on Tuesday to reimburse millions of dollars in legal fees for states that back its proposed $10 billion settlement of opioid lawsuits, but with a..
Reuters - Published

OxyContin maker Purdue gets brief shield from litigation

OxyContin maker Purdue Pharma LP won a court order on Friday briefly pausing the sprawling opioid litigation against the company so it can try to make headway on its proposed legal settlement that it..
Reuters - Published

Judge sees benefit in pausing lawsuits against OxyContin maker Purdue

A U.S. Bankruptcy Judge signaled support on Friday for a six-month pause to litigation led by 24 states against OxyContin maker Purdue Pharma LP to give the company time to settle thousands of lawsuits..
Reuters - Published

U.S. judge urges parties to wisely use Purdue opioid settlement funds

A U.S. bankruptcy judge on Thursday urged parties that will benefit from a proposed settlement with OxyContin maker Purdue Pharma LP to focus on addressing the opioid addiction crisis and avoid..
Reuters - Published

Sacklers reaped up to $13 billion from OxyContin maker, U.S. states say

OxyContin maker Purdue Pharma LP steered up to $13 billion in profits to the company's controlling Sackler family, according to U.S. states opposing efforts to halt lawsuits alleging the company and..
Reuters - Published

U.S. states fight back against Purdue's bid to halt opioid lawsuits

U.S. state officials are due on Friday to launch a counterattack against OxyContin maker Purdue Pharma LP over its attempt to shield the company and its controlling Sackler family from thousands of..
Reuters - Published

Purdue Pharma seeks to halt opioid suits against company, Sacklers

OxyContin maker Purdue Pharma LP on Wednesday asked a U.S. bankruptcy judge to halt for roughly nine months more than 2,600 lawsuits alleging the company and its controlling Sackler family helped fuel..
Reuters - Published

Oxycontin maker Purdue begins bankruptcy in push to settle opioid lawsuits

OxyContin maker Purdue Pharma LP is expected in court on Tuesday to lay out its plan for using bankruptcy to resolve more than 2,600 lawsuits alleging the company fueled the U.S. opioid crisis.
Reuters - Published

What's next for OxyContin maker Purdue Pharma

OxyContin maker Purdue Pharma LP filed for bankruptcy protection after reaching a partial deal to resolve more than 2,600 lawsuits alleging it helped fuel the U.S. opioid crisis.
Reuters - Published

OxyContin maker Purdue Pharma files for bankruptcy protection

OxyContin maker Purdue Pharma LP filed for bankruptcy protection in New York Sunday night, succumbing to pressure from more than 2,000 lawsuits alleging the company helped fuel the deadly U.S. opioid..
Reuters - Published

Purdue Pharma reaches tentative opioid settlement with some: sources

OxyContin maker Purdue Pharma LP reached a tentative agreement with some plaintiffs to resolve litigation over its alleged role in fueling the U.S. opioid crisis and plans to tussle with states..
Reuters - Published

Purdue OxyContin settlement would rank among largest in pharma history

OxyContin maker Purdue Pharma LP has reached a tentative multibillion-dollar agreement with some plaintiffs aimed at settling thousands of lawsuits over its alleged role in the U.S. opioid crisis,..
Reuters - Published

Exclusive: Purdue Pharma nears partial opioid settlement, bankruptcy filing - sources

OxyContin maker Purdue Pharma LP is nearing a partial agreement to resolve widespread litigation over its alleged role in fueling the U.S. opioid crisis and plans to tussle with states opposing its..
Reuters - Published

Exclusive: OxyContin maker prepares 'free-fall' bankruptcy as settlement talks stall

OxyContin maker Purdue Pharma LP is preparing to seek bankruptcy protection before the end of the month if it does not reach a settlement with U.S. communities over widespread opioid litigation, three..
Reuters - Published

Purdue Pharma in discussion on $10 billion-$12 billion offer to settle opioid lawsuits: sources

OxyContin maker Purdue Pharma LP and its owners, the Sackler family, are in discussion to settle more than 2,000 opioid lawsuits against the company for $10 billion to $12 billion, two people familiar..
Reuters - Published

Purdue Pharma 'offers up to $12bn' to settle opioid cases

The firm, owned by the wealthy Sackler family, is facing 2,000 claims over its painkiller OxyContin.
BBC News - Published Also reported by •Reuters

Opioid drugmaker Purdue Pharma offers $10-12 billion to settle opioid claims: NBC News

OxyContin maker Purdue Pharma and its owners, the Sackler family, are offering to settle more than 2,000 lawsuits against the company for $10 billion to $12 billion, NBC News reported on Tuesday,..
Reuters - Published